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Abstract
Background: Ketone bodies have both metabolic and epigenetic roles in cancer. In several studies, they showed
an anti-cancer effect via inhibition of histone deacetylases; however, other studies observed faster tumour growth.
The related molecule butyrate also inhibits growth of some cancer cells and accelerates it in others. This “butyrate
paradox” is thought to be due to butyrate mediating histone acetylation and thus inhibiting cell proliferation in
cancers that preferentially utilise glucose (the Warburg effect); whereas in cells that oxidise butyrate as a fuel, it fails
to reach inhibitory concentrations and can stimulate growth.
Methods: We treated transgenic mice bearing spontaneous MMTV-NEU-NT mammary tumours with the ketone
body β-hydroxybutyrate (β-OHB) and monitored tumour growth, metabolite concentrations and histone
acetylation. In a cell line derived from these tumours, we also measured uptake of β-OHB and glucose, and lactate
production, in the absence and presence of β-OHB.
Results: β-OHB administration accelerated growth of MMTV-NEU-NT tumours, and their metabolic profile showed
significant increases in ATP, glutamine, serine and choline-related metabolites. The β-OHB concentration within the
treated tumours, 0.46 ± 0.05 μmol/g, had no effect on histone acetylation as shown by western blots. Cultured
tumour cells incubated with 0.5 mM β-OHB showed β-OHB uptake that would be equivalent to 54% of glycolytic
ATP phosphorylation and no significant change in glucose consumption or lactate production.
Conclusions: These results suggest that a β-OHB paradox may occur in these mammary tumours in a manner
analogous to the butyrate paradox. At low β-OHB concentrations (<1 mM, as observed in our tumour model post-
treatment), and in the absence of a Warburg effect, β-OHB is consumed and thus acts as an oxidative energy
source and not as an epigenetic factor. This would explain the increase in tumour growth after treatment, the
metabolic profiles and the absence of an effect on histone H3 acetylation.
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Background
Over the last decade, there has been renewed interest in
cancer metabolism, particularly with regard to the repro-
gramming of the metabolic networks within cancer
tissue. Understanding these metabolic perturbations
could open a window for therapeutic intervention. One
such phenotype in cancer is the Warburg effect, often
regarded as a characteristic feature of cancer cells and
solid tumours [1] in which cancer cells perform aerobic
glycolysis instead of the more metabolically efficient
oxidative phosphorylation [2]. The consequent reliance
of cancer cells on glucose has been exploited in meta-
bolic therapies where calorie restriction and ketogenic
diets have also been used to limit glucose metabolism
and thus slow cancer progression [3].
The ketone bodies (KB), β-hydroxybutyrate (β-OHB)
and acetoacetate are synthesised in the liver from acetyl-
CoA and secreted into the blood, from which many
tissues can take up and oxidatively metabolise them.
Their main role is to provide an alternative substrate to
glucose during prolonged starvation; in particular, due to
their ability to cross the blood–brain barrier, they reduce
the reliance of the brain on glucose. β-OHB has been
proposed to be a unique nutritional compound since it
has a calorific value more than glucose or pyruvate and
more efficient provision of energy per molecule of oxy-
gen compared to glucose, pyruvate and free fatty acids
[4]. The metabolism of KB has effects on mitochondrial
energetics and on brain metabolism that have thera-
peutic implications. Ketogenic diets have been used in
refractory epilepsy and have provided some benefit in
hypoxic states, for prevention of muscle-wasting and in
cancer [4].
There have been several studies showing that adminis-
tration of KB or the physiological state of ketosis had an
anti-cancer effect [3, 5–7]. Paradoxically, however, in
another group of studies KB were found to promote the
growth of cancers [8–10]. On the anti-cancer side, stud-
ies on orthotopically implanted mouse astrocytomas
have reported that malignant brain tumours are poten-
tially manageable with dietary therapies that reduce glu-
cose and elevate KB, since these brain tumours lack
metabolic versatility and are dependent largely on glu-
cose for energy [5]. More recent studies have evaluated
the anti-cancer and anti-cachectic properties of KB in
cultured pancreatic tumour cells as well as the effect of
ketogenic diets on tumour burden and cachexia in
orthotopically implanted models of pancreatic cancer
[7]. The authors proposed that KB-induced metabolomic
reprogramming by ketogenic diets suppresses cancer
and cancer-induced cachexia. In another study, Poff
et al. [3] showed that dietary administration of ketone
precursors extended the survival time of mice with
metastatic cancer by 50–70%. In contrast, other studies
on breast cancer have shown that KB utilisation drives
tumour growth and metastasis [8–10]. One of these
papers demonstrated that KB, when administered system-
ically to animals bearing a breast tumour xenograft, pro-
moted the growth of those tumours with no significant
increase in angiogenesis and with a transcriptional shift
towards oxidative mitochondrial metabolism in cancer
epithelial cells relative to adjacent stromal cells [8].
In addition to their metabolic role, KB are also inte-
grated into the regulation of epigenetic states and
transcription, thus providing potential mechanisms that
link cellular energy metabolism and regulation of gene
expression via chromatin modification [11, 12]. β-OHB,
for instance, is an endogenous inhibitor of the histone
deacetylases (HDACs; also termed lysine deacetylases)
which remove acetyl epigenetic marks from histones and
other proteins that interact with DNA. Acetyl-CoA, in
addition to being the substrate for synthesis of KBs, is
also the co-factor of the histone acetyltransferase
enzymes (HATs) that incorporate acetyl groups into
histones [13]. Deregulation of histone acetylation results
in abnormal expression profiles of genes involved in cell
proliferation and differentiation and is associated with
malignancy [14].
Butyrate, closely related to β-OHB, has been an essen-
tial agent for determining the role of histone acetylation
in chromatin function, and observations that butyrate-
treated cells show histone hyperacetylation led to the
discovery that butyrate inhibits HDAC activity [15]. Its
role in linking energy metabolism with epigenetics has
been reported by Donohoe et al. [16]. Butyrate is a
short-chain fatty acid produced by fermentation of diet-
ary fibre in the colon, where it is metabolised oxidatively
and functions as a primary energy source for colono-
cytes. Notably, butyrate has been shown to have growth-
inhibitory effects in cancerous cells but either no effect
or stimulation of growth in non-cancerous cells. These
opposing effects on normal versus cancerous cells have
been termed the butyrate paradox (reviewed by Lupton
2004) [17]. It is thought that this paradox results from
epigenetic effects of butyrate on the two cell types.
Donohoe et al. [16] suggest that the mechanism of
butyrate-mediated histone acetylation and cell prolifera-
tion could be dictated by the Warburg effect. In cancer
cells that exhibit the Warburg effect and therefore derive
their energy from glycolysis, butyrate is metabolised in-
efficiently; it therefore accumulates and functions as an
HDAC inhibitor. In normal cells, butyrate functions as
an oxidative energy source, stimulating proliferation, and
its concentration is thereby reduced below the level
required for HDAC inhibition.
Not all cancer cells display the Warburg effect. For
instance, HeLa cells can adapt their mitochondrial
network structurally and functionally to derive energy
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exclusively by oxidation of glutamate [18] and in pros-
tate cancer cells, fatty acid oxidation is a dominant bio-
energetic pathway [19]. Furthermore, Lisanti has
described a “reverse” Warburg effect in which cancer
cells utilise lactate secreted by adjacent host cells [20]. It
seems probable, therefore, that any cancer cells that nor-
mally utilise oxidative metabolism would be likely to
oxidise butyrate in the same way as normal host cells
and thus reduce their internal concentration of butyr-
ate below the level required to induce HDAC inhib-
ition so that they would not, therefore, display the
butyrate paradox.
Previous studies on the action of KB on the growth of
tumours have used transplanted tumours. These models
have limitations, in particular for studies like the present
one, with regard to the metabolic interactions between
tumour cells and the adjacent “host” cells in the tumour
microenvironment. The architecture of a transplanted
tumour is different from that of a spontaneous tumour:
subcutaneously implanted tumours, in particular, usually
have poor blood supplies and therefore tend to be more
hypoxic than spontaneous tumours, while many of the
standard transplanted models have become selected,
during repeated passages, to thrive in their unnatural
environment. In addition, transplanted tumour models
often utilise cells that have been pre-selected for rapid
growth in an unnatural cell culture environment. These
limitations are all circumvented by the use of genetically
engineered models in which tumours arise spontan-
eously in the “autochthonous” tissue.
In the MMTV-NEU-NT transgenic mice used in the
present study, tumours arise spontaneously in the mam-
mary tissue by overexpression of the activated form of
the NEU/HER2 oncogene, similar to the ERBB2 gene
that is amplified in many human breast cancers [21, 22].
We have investigated the effect of β-OHB on the growth,
energy metabolism and histone H3 acetylation of MMTV-
NEU-NT spontaneous mammary tumours. We also inves-
tigated the effect of β-OHB on the uptake of glucose and
lactate production in cultured cells of the same tumour
type to get a measure of their glycolytic rate.
We have used both 1H and 31P magnetic resonance
spectroscopy (MRS) to monitor metabolites in the
tumours and livers of MMTV-NEU-NT transgenic mice
that have been treated with β-OHB intraperitoneally
(ip). MRS allows the simultaneous detection of numer-
ous metabolites related to glucose, protein and lipid
metabolism and is a valuable tool both in vivo and in
vitro for detecting metabolic features of tumours and
comparing them with those of normal tissue both during
normal progression and after treatment [23]. Biomarkers
for tissue bioenergetics, such as nucleoside triphosphate
(NTP), inorganic phosphate (Pi), creatine (Cr) and
phosphocreatine (PCr); glycolytic markers such as
glucose and lactate; amino acids such as glycine, alanine,
leucine, isoleucine, glutamine and glutamate; ketone bod-
ies and intermediary metabolites like β-OHB, acetate, suc-
cinate and choline-containing phospholipid metabolites
are all readily observed with MRS methods.
Activated choline metabolism is a hallmark of many
cancers and is characterised by increases in the phos-
phocholine (PC) and total choline (tCho) peaks. That
change, referred to as the choline phenotype, was discov-
ered mainly in MRS studies on tumours [24]. Subsequent
studies have identified malignant transformation rather
than just cell proliferation as the cause of abnormal
choline metabolism in cancers [25]. Choline-containing
metabolites provide information on tumour membrane
metabolism, since the phosphomonoesters (PMEs) PC
and phosphoethanolamine (PE) are precursors of the
phosphatidylcholine and phosphatidylethanolamine in
biological membranes and the phosphodiesters (PDEs)
glycerophosphocholine (GPC) and glycerophosphoetha-
nolamine (GPE), are breakdown products of phosphatidyl-
choline and phosphatidylethanolamine.
Methods
Materials
DL-β-hydroxybutyric acid (sodium salt) was purchased
from Sigma-Aldrich and made up in phosphate buffered
saline (PBS) at 50 mg/ml, pH to 7.4 with 0.1 M hydro-
chloric acid. Perchloric acid (PCA) and potassium hy-
droxide were purchased from Merck (Poole, UK).
Sodium 3-trimethylsilyl-2,2,3,3-tetra-deuteropropionate
(TSP) was purchased from Goss Scientific Instruments
Ltd, UK. All other chemicals not specified were pur-
chased from Sigma (Poole, UK).
MMTV-NEU-NT tumour model
Female transgenic mice expressing the mutant-activated
form of rat NEU (NEU-NT) under transcriptional con-
trol of the MMTV promoter (MMTV-NEU-NT mice)
were purchased from Charles River, UK. The mating
strain is the FVB/N mouse and multiple tumours involv-
ing the entire mammary epithelium arise synchronously
in the mammary gland area [21] between 18 and
20 weeks of age in 35–50% of the mice.
Mice were maintained under strict inbreeding condi-
tions; health was monitored every 3 months and the
presence of the Neu transgene was routinely checked by
PCR on tail DNA. Animals were anaesthetized with an
isoflurane/oxygen mixture. All experiments were per-
formed in accordance with the UK Animals Scientific
Procedures Act 1986 and within the NCRI guidelines for
the cancer research community concerning the use and
welfare of experimental animals in oncology [26]. All
possible measures were taken to minimise any pain or
discomfort to the animals.
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Tumour-bearing mice were anaesthetized, tumour size
measured and mice injected intraperitoneally with β-
OHB at 500 mg/kg body weight daily for 3 weeks. A
control group was injected with PBS daily at 10 ml/kg body
weight. Tumour volume was measured weekly. Tumour
volume was calculated using the formula (π/6)(d1 · d2 · d3)
where d1, d2 and d3 are the three orthogonal diameters
measured by callipers to derive an ellipsoidal volume. At
day 21, part of the tumour and liver were freeze-clamped
for metabolite analysis and western blots and part was
placed in 10% neutral buffered formalin (formalin) for
histological staining. The liver was used as the normal
tissue because the mouse mammary organ is a diffuse,
subcutaneous sheet of tissue that cannot be separately
freeze-clamped for metabolic studies.
High-resolution 1H and 31P MRS of tumour extracts
Part of the freeze-clamped tumour was extracted with
four volumes of 6% perchloric acid and centrifuged at
1000 g for 10 mins. The supernatants were neutralised,
freeze-dried, reconstituted in deuterium oxide and trans-
ferred to 5-mm NMR tubes. MR spectra were acquired at
room temperature on a 600-MHz Bruker spectrometer
(Bruker Biospin, Coventry, UK).
1H MRS: The water resonance was suppressed by
using gated irradiation centred on the water frequency.
TSP (50 μl, 5 mM) was used for chemical shift calibra-
tion and quantitation.
31P MRS: Metal ions were chelated by addition of
EDTA (ethylenediaminetetraacetic acid, 50 μl, 60 mM)
and MDP (methylenediphosphonic acid, 50 μl, 5 mM)
was added to each sample for chemical shift calibration
and quantitation.
Metabolite concentrations were determined by peak in-
tegration, normalised to the peak integral of the respective
internal standard (TSP for 1H and MDP for 31P MRS).
Histology
The formalin-fixed part of the tumour was embedded in
paraffin wax and 3-μm sections cut de-waxed and rehy-
drated as standard. Slides were stained immunohisto-
chemically for CD31, Ki-67 and cleaved caspase 3 using
a biotin-free bond polymer refine detection kit (Leica
Cat No DS9800) and the automated Bond staining plat-
form. Additional slides were stained for TUNEL using a
hybrid Bond-manual-Bond protocol.
CD31 staining: Antigen retrieval was by proteinase k
enzyme digestion (AR 9551, Leica) at 37 °C for 10 mins.
The primary antibody was the rat anti-mouse CD31,
1:400 (BD Pharmingen, 553370), and the secondary anti-
bodies were goat anti-rat 1:500 (Jackson Immuno Re-
search 12-005-167) and rabbit anti-goat 1:500 (Jackson
Immuno Research 305-005-045).
Ki-67 staining: Antigen retrieval was by sodium citrate
digestion at 100 °C for 20 min, and the primary antibody
was the rabbit anti Ki-67, 1:1000 (Bethyl Laboratories,
IHC-00375).
Cleaved caspase 3 staining: Antigen retrieval was by
Tris EDTA for 20 min at 100 °C; the primary antibody
was rabbit mAb 9664 used at 1:200 (Cell Signalling
Technology).
TUNEL staining: Slides were pre-treated at 37 °C for
10 min in Bond enzyme concentrate containing a pro-
teolytic enzyme and stabiliser (AR9551) followed by a
peroxidase block for 5 min (Leica kit). Slides were then
processed manually for the hybridisation step in rTdT
reaction mix at 1:1000 for 60 min at 37 °C (Promega
kit), for 3 × 15 min stringency washes using SSC at 1:20
(Promega kit) and 30-min incubation with SA-HRP at
1:500 (Leica kit). They were returned to the Bond
platform for subsequent 10-min refining with 3-3′Di-
aminobenzidine (DAB) (Leica kit) and 5-min staining
with haematoxylin (Leica kit). Two sequential slides
were cut from each block for positive and negative
staining; for negative staining the enzyme in the reaction
mix was replaced by distilled water. Values for the nega-
tive slide were subtracted from those for the adjacent
positive slide after scanning and analysis.
The DAB enhancer used for all staining was AR
9432 (Leica).
Analysis: Slides were scanned with an Aperio Scan-
scope AT2 at ×20 magnification and resolution of 0.5
microns per pixel. Automated analysis of CD31 (micro-
vessel density) staining was performed using the Aperio
Imagescope algorithm “Microvessel Analysis version 1”.
Halo software (Indica Labs) “Cytonuclear version 1.4”
was used for automated analysis of Ki-67 staining to
identify nuclei, count and grade them according to stain
intensity and for automated analysis of CC3 and TUNEL
staining using positive pixel count to measure the total
stained area. All algorithms excluded necrotic regions
and the lacunae typical of these tumours [27, 28]; hence,
all values for histological parameters were expressed per
viable tissue area.
Western blotting
Total cell extracts from freeze-clamped, pulverised
tissues were obtained by incubation on ice for 10 min in
cell lysis buffer (RIPA, Pierce) supplemented with pro-
teinase inhibitors (1 × Complete (Roche), 1:500 PI cock-
tail (Sigma)) and 10 mM sodium butyrate (Sigma)).
Lysates were sonicated (Bioruptor; 3 × 30 s, high setting)
and spun at 13000 rpm, 4 °C for 30 s. Thirty microgram
protein extracts were run on 4–20% Bis-Tris gradient
gels (Invitrogen), transferred onto PVDF membranes
(GE Healthcare) and stained with Ponceau S (Sigma).
The blotted membranes were cut at ~40 KDa and
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blocked with 3% skimmed milk in TBS-T (TBS/0.02%
Tween-20) for 1 h at room temperature. All antibody
incubations were in 1% milk/TBS-T for 1 h at room
temperature and washes between antibodies in TBS-T.
The bottom half was incubated with rabbit anti-H3Ac
(Millipore, 06-599, 1:10,000) and the top half with rabbit
anti-LaminB1 (Abcam, ab16408, 1:1000). After 3 ×
5 min washes, top and bottom half membranes were in-
cubated with donkey anti-rabbit IR-Dye 800 (LI-COR,
926-32213), washed and scanned on a LI-COR Odyssey
scanner. Fluorescence intensity signals were quantified
with ImageQuant (GE Healthcare).
Cell culture and 1H NMR analysis
A cell line of C-neu/HER2-induced mammary carcinoma
cells was established in-house from a tumour mass
excised from an MMTV-NEU-NT mouse. Tumour cells
were cultured in high glucose Dulbecco’s modified
eagle’s medium (DMEM) (4.5 g/L, Gibco 41966) supple-
mented with 10% foetal calf serum (FCS), 1000 U/ml
penicillin and 100 μg/ml streptomycin. Before treatment
with β-OHB, cells were seeded in 6-well plates at a dens-
ity of 7 × 105 per well containing low-glucose DMEM
(1 g/L, Gibco 12320) supplemented with 10% FCS,
1000 U/ml penicillin and 100 μg/ml streptomycin. β-
OHB was added at concentrations 0, 0.5, 5 and 10 mM.
Twenty-four hours after treatment, the medium in each
well was analysed for glucose and lactate by 1H MRS on
a 600-MHz Bruker Spectrometer with DSS (4, 4-
dimethyl-4-silapentane-1-sulfonic acid) (10 μl, 120 mM)
as a standard for chemical shift calibration and quantita-
tion. Cells in each well were removed with 0.05% trypsin
and counted on a LunaTM automated cell counter using
trypan blue exclusion for viability. Results are expressed
as micromole glucose consumed or micromole lactate
produced/106 viable cells/24 h.
Statistical analysis
The solid tumour, tumour extract, tumour cell and
histological data are presented as the mean ± SEM. Two-
tailed unpaired Student’s t tests were used for compari-
son of tumour volumes, metabolite concentrations and
histological data, and a p value of <0.05 was considered
to be statistically significant.
Results
Effect of β-OHB on tumour volume and growth rate
The MMTV-NEU-NT mouse strain develops multiple
tumours within the mammary gland between 18 and
20 weeks of age. The mice that were treated with ip β-
OHB showed a significant increase in tumour growth
rate (Fig. 1a) over the 3-week treatment (p = 0.04) with
significant increases during week 1 and week 2 (p =
0.003 and p = 0.035 respectively) (Fig. 1b). The tumour
growth rate in the control mice over the 3-week
period was 21 ± 3 mm3/day compared to 38 ± 7 mm3/
day in the treated cohort (p = 0.04, Fig. 1b). The mean
doubling time decreased from 14.2 ± 5 days in the
control group to 11.6 ± 4.7 days in the treated cohort
(p = 0.11, Fig. 1a). Tumour volume increased over the
3-week period from 0.21 ± 0.02 to 0.65 ± 0.09 cm3 in
the control and 0.32 ± 0.03 to 1.22 ± 0.15 cm3 in the
treated cohorts (Fig. 1a).
Effect of β-OHB on tumour branched chain amino acids,
glutamine and glycine
The tumours of mice treated with β-OHB contained
significantly higher concentrations of glutamine and
glycine but no change in the branched chain amino acids
(Fig. 2a). The glutamine levels increased from 0.54 ± 0.07
in the controls to 0.86 ± 0.08 μmol/g in the treated
Fig. 1 a Tumour volume in MMTV-NEU-NT tumour-bearing control
mice and mice treated with β-OHB (500 mg/kg), injected ip daily for
3 weeks. Control: N= 25 tumours (18 mice), Treated: N= 23 tumours
(19 mice); * p< 0.005. b Tumour growth rates (cm3/day) post-treatment
with β-OHB (500 mg/kg), injected ip daily for 3 weeks during week 1
(days 0–7), week 2 (days 7–14), week 3 (days 14–21) and overall, weeks
1–3 (days 0–21); ** p< 0.005, * p < 0.05
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tumours (p = 0.004) and the glycine from 0.28 ± 0.06 to
0.49 ± 0.08 μmol/g (p = 0.04, Fig. 2a). The increases in
the branched chain amino acids (leucine, isoleucine and
valine) were not significant (p > 0.14). The livers of the
treated mice showed a significant increase in glycine
from 0.73 ± 0.16 in the controls to 1.81 ± 0.19 μmol/g
(p = 0.008) after β-OHB treatment, whereas glutamine
or branched chain amino acids did not show a significant
change (Fig. 3).
Effect of β-OHB on tumour glycolytic intermediates,
choline, creatine and phosphorus-containing
metabolites
On treatment with β-OHB, the tumour lactate in-
crease from 4.44 ± 0.39 to 5.33 ± 0.47 μmol/g and
glucose decrease from 0.73 ± 0.07 to 0.62 ± 0.05 μmol/
g were not significant (p = 0.15 and 0.23 respectively)
(Fig. 2b). However, there was a significant increase in
liver lactate from 5.13 ± 0.68 to 7.49 ± 0.86 μmol/g
(p = 0.032) (Fig. 3). There was also a significant increase in
tumour tCho (p = 0.03) caused chiefly by an increase in
PC from 0.73 ± 0.06 to 1.0 ± 0.11 μmol/g (p = 0.03). The
decrease in PCr from 0.5 ± 0.07 to 0.34 ± 0.04 μmol/g was
not significant (p = 0.09) (Fig. 2c). 31P MRS also showed a
significant increase in the PME peak, consisting
mainly of PE and PC, from 2.48 ± 0.27 μmol/g in the
control to 3.28 ± 0.25/g in the treated tumours
(p = 0.04). There was a small but significant increase
in the ATP levels, from 0.3 ± 0.05 to 0.43 ± 0.04 μmol/g
(p = 0.05) (Fig. 4).
Fig. 2 Metabolites (μmol/g) measured by 1H MRS in tumour extracts at day 21 from MMTV-NEU-NT tumour-bearing control mice and mice
treated with β-OHB (500 mg/kg), injected ip daily for 3 weeks. a Branched chain amino acids, glutamine and glycine,** p < 0.005, * p < 0.05.
b Lactate and glucose. c Choline-containing metabolites: choline, phosphocholine (PC), total of choline + phosphocholine; creatine containing
metabolites: creatine (Cr), phosphocreatine (PCr), ratio of PCr/Cr. * p < 0.05 (D) β-OHB and acetate; amino acids alanine, aspartate and glutamate;
succinic acid and myo-inositol. Control: N = 22 tumours (13 mice); Treated: N = 33 tumours (19 mice), *p < 0.05. d other metabolites
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Effect of β-OHB on tumour ketone body levels,
myo-inositol and amino acids alanine, aspartate
and glutamate
Levels of β-OHB and acetate were higher in the tu-
mours of treated mice compared to controls (p = 0.04
and p = 0.13 respectively) whereas myo-inositol was
lower in the treated tumours (p = 0.06) (Fig. 2d).
Effect of β-OHB on global histone H3 acetylation levels of
MMTV-NEU-NT tumours and livers
We looked at the effect of β-OHB on global histone H3
acetylation by western blotting and found that the tu-
mours and livers from mice treated with β-OHB showed
no significant change in the pan-histone 3 acetylation
levels (H3ac) compared to control tumours and liver re-
spectively (Fig. 5). Lamin B was used as the loading con-
trol. The relative intensity of H3ac in the treated
tumours was 0.713 ± 0.005 (n = 10) compared to 0.758 ±
0.034 (n = 15) in the control tumours (p = 0.22). In the
treated and control livers, the mean intensity was 0.71 in
each case.
Effect of β-OHB on tumour vasculature, proliferation
and apoptosis markers as measured by
immunohistochemistry
There was no significant change in tumour vascula-
ture as measured by CD31 immunohistochemistry
(97.2 ± 12.2 in the control compared to 133.2 ±
18.0 vessels/mm2 in the treated tumours, p = 0.13) or
in tumour proliferation as measured by Ki-67 stain-
ing (28.9 ± 4.0% positive in the control compared to
21.7 ± 3.9% positive in the treated, p = 0.22). Similarly,
staining for cleaved caspase 3 and TUNEL showed
no significant differences between treated and control
tumours (Table 1). Fig. 6 shows representative images
of markers for vasculature, proliferation and an
apoptosis marker.
Fig. 3 Metabolites (μmol/g) measured by 1H MRS in liver extracts at day 21 from MMTV-NEU-NT tumour-bearing control mice and mice treated
with β-OHB (500 mg/kg) injected ip daily for 3 weeks. Isoleucine, valine, glutamine, glycine, lactate, glucose, ATP + ADP, choline, phosphocholine (PC),
glycerophosphocholine (GPC), creatine (Cr), phosphocreatine (PCr), myo-inositol. Control: N = 12; Treated: N = 8; *p < 0.05, ** p < 0.01
Fig. 4 Phosphorus containing metabolites (μmol/g), measured by 31P
MRS, in tumour extracts at day 21 from MMTV-NEU-NT tumour-bearing
control mice and mice treated with β-OHB (500 mg/kg), injected ip
daily for 3 weeks. Phosphomonoesters (PME = phosphocholine (PC) +
phosphoethanolamine (PE)), phosphodiesters (PDE = glycerophospho-
choline + glycerophosphoethanolamine), inorganic phosphate (Pi), and
β-ATP/Pi. Control: N = 8 to 13 (6 mice); Treated: N = 13–18 (12 mice),
*p≤ 0.05
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Effect of β-OHB concentration on β-OHB uptake, glucose
uptake and lactate output in MMTV-NEU-NT tumour cells
in culture
C-neu/HER2 cells were cultured in the presence of 0,
0.5, 5 and 10 mM β-OHB and the growth medium was
analysed for β-OHB, glucose and lactate at 0 and 24 h.
The cells secreted about 33% more lactate than they
consumed glucose. Allowing for the fact that two mole-
cules of lactate are produced from each glucose, this im-
plies that about 2/3 of the glucose was metabolised to
lactate via glycolysis. When the cells were cultured in
medium containing 0.5 mM β-OHB, a level similar to
that measured in treated tumours in vivo, the uptake of
β-OHB was 260 ± 71 nmol/106 cells/24 h. When the
cells were cultured in medium containing 5 mM β-OHB,
the β-OHB uptake was 420 ± 264 nmol/106 cells/24 h
and at 10 mM β-OHB, it was 834 ± 551 nmol/106 cells/
24 h. However, these higher β-OHB uptake values at
higher β-OHB concentrations were not significantly dif-
ferent from those at 0.5 mM β-OHB because of the wide
scatter in the results.
When the cells were cultured at 0.5 mM β-OHB, there
was no significant difference in glucose consumption
compared with culture in medium without β-OHB.
However, at the higher β-OHB levels of 5 mM and
10 mM, a significant decrease in glucose consumption
was observed relative to controls (p < 0.005) (Fig. 7).
Surprisingly, in view of the decreased glucose consump-
tion by cells grown in 5 or 10 mM β-OHB, there was no
significant difference in lactate production in any of the
treated cells when compared to controls (Fig. 7).
Discussion
The results presented here indicate that daily ip injec-
tions of the ketone body β-OHB over a 3-week period
significantly increased tumour growth rate in this au-
tochthonous mouse mammary tumour model, although
no changes were seen in proliferative fraction, blood
vessel density or apoptosis. This suggests that the cycle
time of the tumour cells was decreased by the treatment.
Calculation of the cell cycle time for each group from
the respective doubling time (Fig. 1a) and proliferative
index (Table 1) gives a cycle time of 4.7 days for the
controls and 3.6 days for the treated tumours.
The growth-promoting properties of β-OHB seen in
this study are similar to those observed by Lisanti’s
group [8–10] in breast cancer xenografts and cultured
breast cancer cells, but contrary to the growth-inhibitory
effects of KB that have been reported in other cancers
and in metastasis [3, 5, 7]. Like those of Lisanti’s
group, our data were obtained from a breast cancer
model, which suggests that the opposing responses of
tumours to ketones may be tumour-type dependent,
rather than a general phenomenon, and may perhaps
be dictated by the different genetic drivers of tumours
arising in different tissues.
Since β-OHB is closely related to butyrate, our results
in the mammary tumours could be interpreted by a
mechanism analogous to the “butyrate paradox” de-
scribed by Donohoe et al. [16] that explains the oppos-
ing effects of butyrate on inhibiting growth of cancer
cells and promoting growth of normal cells. They argue
that cancer cells that show the Warburg effect favour
glycolysis over oxidative metabolism of substrates such
as butyrate; butyrate therefore accumulates and inhibits
cancer cell proliferation by acting as an HDAC inhibitor.
In contrast, butyrate oxidation by normal cells reduces
butyrate concentrations below the level needed for
HDAC inhibition; KB oxidation will then be an energy
source for non-cancerous cells, and can allow them to
grow faster. It seems likely that in cancerous cells that
Fig. 5 Western blots for global histone H3 acetylation (H3Ac) and
LaminB in MMTV-NEU-NT tumour and liver extracts. Tissues from
treated mice (daily ip injection of 500 mg/kg β-OHB) and control
mice were freeze-clamped at day 21. A representative blot is shown.
Across the entire sample set, the mean (±se) intensity of global
H3Ac relative to LaminB in treated tumours (n = 10) was 0.713
(±0.005) compared to 0.758 (±0.034) in the control tumours (n = 15),
p = 0.22. In the treated livers, the mean intensity was 0.706 (n = 2)
compared to 0.711 ± 0.002 (n = 4) in the control livers
Table 1 Quantitative histological analysis of viable areas of tumour sections (control and β-OHB treated) stained for CD31 (microves-
sel density as number of vessels/mm2), Ki-67 (proliferative index as % positive cells), cleaved caspase 3 and TUNEL (percent positively
stained area)—see Fig. 6. Values are mean ± SEM
CD31 (microvessel density:
vessels/mm2)
Ki-67 Index (% positive cells) CC3 (% positively stained area) TUNEL (% positively stained area)
Control (N = 7) 97.2 ± 12.2 28.9 ± 4.0 1.54 ± 0.36 3.30 ± 1.08
β-OHB treated (N = 8) 133.2 ± 18.0 21.7 ± 3.9 0.83 ± 0.26 2.55 ± 1.40
p (t test) 0.13 0.22 0.13 0.69
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do not display the Warburg effect (i.e., those that can
oxidise glucose and other substrates and do not rely ex-
clusively on glycolysis for ATP phosphorylation) β-OHB
could be metabolised in the same way as in the normal cells
studied by Donohoe et al., so that its concentration will fall
below that required for growth-inhibitory HDAC inhibition
and the ATP generated will facilitate proliferation.
Our treatment regime resulted in β-OHB levels of 0.46 ±
0.05 μmol/g within the tumours (Fig. 2d), a concentration
that had no effect on histone acetylation (Fig. 5). Was the
low β-OHB concentration due to it being metabolised? Our
results on cultured C-neu/HER2 cells incubated with
0.5 mM β-OHB (approximately the concentration that we
had found in solid tumours) showed that the cells took up
0.26 ± 0.71 μmol β-OHB/106 cells/24 h, implying that
metabolism of β-OHB would indeed have reduced its
concentration in the tumours (Table 2).
In the absence of β-OHB the output of lactate from
the C-neu/HER2 cells (8.2 μmol/106 cells/24 h (Table 2))
was equivalent (since two lactates are formed from each
glucose) to about 70% of their glucose uptake; thus,
around 30% of the glucose would have been available for
anabolic metabolism or, if the cells were not fully glyco-
lytic, for oxidative respiration. Addition of 0.5, 5.0 or
10.0 mM β-OHB to the culture medium had little effect
on lactate output (Table 2) so it seems likely that the
ATP production from β-OHB oxidation was additional
to that obtained from glycolysis. Using Murray’s estimate
of 13 ATP per β-OHB [29], an uptake of 0.26 μmol β-
OHB/106 cells/24 h (as observed when 0.5 mM β-OHB
was added to the culture medium) would phosphorylate
3.38 μmol ATP compared to the 6.3 μmol ATP obtained
by glycolytic formation of 6.3 μmol lactate/106 cells/
24 h. Thus, if the cultured cancer cells had been relying
a b
c d
e f
Fig. 6 Ki-67 (proliferation marker, panels a and b), CD31 (measure of vascularity, panels c and d) and cleaved caspase 3 (apoptosis marker, panels
e and f) immunohistochemical staining of tumour sections at day 21 from control mice (left) and mice treated with β-OHB (500 mg/kg), injected
ip daily for 3 weeks (right) (Bars show 100 μm). See Table 1 for quantitative analysis
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entirely on glycolytic ATP phosphorylation (i.e., the
Warburg effect) in the absence of β-OHB, then provision
of 0.5 mM β-OHB (approximately the concentration
found in the solid tumours when the mice were injected
with β-OHB) would have increased their ATP output by
about 50% (see Table 2).
When the cells were incubated with 5 mM β-OHB (i.e.,
a 10-fold higher concentration than was observed in the
solid tumours) β-OHB uptake increased to 0.42 μmol/
106 cells/24 h whereas glucose consumption decreased to
4.0 μmol/106 cells/24 h and lactate output remained at
6.0 μmol/106 cells/24 h, indicating that 75% of the glucose
uptake was used in glycolysis (Fig. 7) and that the ATP
output from β-OHB oxidation would have been around
90% of that provided by glycolysis. The most extreme case
we considered was culture in 10 mM β-OHB (about 20-
fold higher than the concentration observed in the solid
tumours) when the β-OHB uptake increased to 0.83 μmol
β-OHB/106 cells/24 h and lactate output to 7.3 μmol/
106 cells/24 h but the glucose consumption stayed at
4.3 μmol/106 cells/24 h (Fig. 7), implying that around 85%
of the glucose uptake was consumed in glycolysis and that
β-OHB oxidation would have provided about 50% more
ATP than glycolysis (Table 2).
Taken all in all, it is evident from the cell culture
studies that the C-neu/HER2 cancer cells would have
substantially increased their ATP output by oxidising β-
OHB, even when it was present at the low concentration
observed in the solid tumours in vivo, and that oxidation
of β-OHB seems to have substituted for oxidative me-
tabolism of glucose. If that effect also took place in the
solid tumours (i.e., if they were able to increase their
ATP output substantially by oxidising β-OHB, and
perhaps also redirect the glucose from oxidation into
anabolic synthesis, both of which effects would be
growth-promoting), then it seems likely that these
mechanisms would have reduced the concentration of β-
OHB to a level that did not inhibit HDAC and that the
cells would have had more ATP and perhaps also glyco-
lytic intermediates for faster growth. The enhanced
growth rate and absence of histone acetylation change
would thus constitute a β-OHB paradox.
In addition, Donohoe et al. [16] showed that butyrate
(0.5 mM) inhibited ATP citrate lyase, which also induced
a stimulatory effect on cell growth, though reduced by a
factor of 3, which they attributed to butyrate having a
stimulatory effect by increasing acetyl-CoA production
for lipid biosynthesis and/or acetylation of lysine resi-
dues. They also showed that there was no increase in
histone H3 acetylation with low doses of butyrate when
the Warburg effect was blocked. Their results demon-
strate elegantly that the Warburg effect can be a cause
rather than an effect of changes in histone acetylation
and that cancer metabolism can drive the epigenetic
profile of cancer cells away from the cell of origin and
contribute to tumourigenesis. Another recent study
demonstrates that the rate of glycolysis quantitatively
mediates specific histone acetylation sites, and the
authors suggest that a possible function of the Warburg
effect is to confer specific signalling effects on cells by
altering the levels of multiple key metabolites that serve
as cofactors and substrates for reactions involved in
post-translational protein modifications [30]. We did not
consider these latter issues in our study.
The tumours in the β-OHB-treated mice showed a
number of other features characteristic of enhanced
growth rate. There were significant increases in the 1H
MRS peaks for choline and PC plus choline, and also in
Fig. 7 Effect of β-OHB (0, 0.5, 5, 10 mM) on glucose consumption and
lactate production (μmol/106 cells/24 h) at 24 h when MMTV-NEU-NT
cells were incubated in low-glucose (1 g/L) DMEM. N = 3, **p < 0.005
Table 2 Effect of β-OHB in the culture medium on uptake of β-OHB, uptake of glucose and output of lactate. Uptake and output
data are the means from the experiment shown in Fig. 7, N = 3
β-OHB in medium (mM) β-OHB uptakea Glucose uptakea Lactate outputa β-OHB ATP as % of lactate ATP
0 – 6.0 8.2 –
0.5 0.26 5.8 6.3 54%
5 0.42 4.0 6.0 91%
10 0.83 4.3 7.3 148%
aμmol/106 cells/24 h
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the 31P MRS PME peak, which includes PC, while the
PDE peak, which includes GPC, was lower in the treated
tumours but the change was just outside the significant
range (p = 0.06). These effects are all in keeping with the
upregulated choline metabolism that is characteristic of
progressing tumours [31, 32]. PC is both a precursor
and a breakdown product of phosphatidylcholine, the
main phospholipid component of cell membranes, while
GPC is a breakdown product. During the increased rates
of membrane turnover that are characteristic of tumour
growth, all these signals tend to be elevated, both in the
tumour cells and host cells in the tumour microenviron-
ment, a phenomenon that is termed the choline pheno-
type. Elevation of tCho levels has been associated with
aggressiveness in breast cancer [32] and prostate cancer
[33], and it has been used in the grading of brain tu-
mours [34]. In breast and ovarian cancers, the low PC
and high GPC in non-malignant cells change to high PC
and low GPC after malignant transformation [31, 35].
Our results are therefore consistent with induction of
the choline phenotype in the treated tumours and thus
with their increased growth rate.
Treatment of the tumours with β-OHB also resulted
in significantly increased concentrations of the amino
acids glutamine and glycine (Fig. 2a). The carbon
skeletons of glycine (via conversion to serine and then
pyruvate) and glutamine (via conversion to glutamate
and then α-ketoglutarate, passage through the tricarb-
oxylic acid (TCA) cycle and then formation of pyru-
vate) can be ultimately converted to acetyl-CoA and
oxidised in the tricarboxylic acid cycle. This is the
same pathway as is utilised for β-OHB oxidation, so
perhaps the elevated concentrations of glycine and
glutamine in β-OHB-treated animals can be explained
by competition for that breakdown pathway. Glutam-
ine, a versatile nutrient that has a role both in oxida-
tive phosphorylation and macromolecular synthesis, is
required for survival and growth of a variety of tu-
mours [36]. It also modulates proliferative signalling
mechanisms such as the activation of the serine/
threonine kinase mTOR [37]. Not all cancer cells
need an exogenous supply of glutamine, however.
Breast cancer cells have shown systematic differences
in glutamine dependence, with basal-type cells being
glutamine dependent and luminal-type cells being glu-
tamine independent [38]. An analysis of glutamine
metabolism in lung and liver tumours revealed that
both tissue of origin and the cancer-inducing onco-
gene influence whether tumours produce or consume
glutamine [39]. Although tumours differ in their need
for glutamine, the increase in glutamine concentration
that we observed after β-OHB treatment is consistent
with increased energy requirements and macromol-
ecular synthesis in progressing tumours.
The recent surge of interest in the study of metabolic
processes in cancer has focussed mainly on glucose and
glutamine metabolism, but the serine and glycine path-
ways are now also thought to be perturbed in tumours
[40]. In a recent metabolic flux analysis across a panel of
CL-60 tumour lines, Jain et al. showed an unexpectedly
increased reliance on glycine metabolism in proliferating
cells, a phenotype that was not observed in proliferating
non-transformed cells [41]. They showed that glycine is
utilised for de novo purine nucleotide biosynthesis while
others have shown that glycine and related metabolites
including serine and threonine are central to cellular
transformation [42, 43]. The significant increase in gly-
cine we observed in tumours treated with βOHB is thus
in keeping with the phenotype of proliferating and/or
transformed tissue. The decrease in myo-inositol with
increase in tumour growth rate that we observed is also
in keeping with what has been previously observed in
breast cancer where myo-inositol is lower in breast
tumour tissue compared to normal tissue [44]. The
role of myo-inositol in cancer is unclear but it is
thought to be involved in hormone signal transduc-
tion and as an osmoregulator at different stages of
malignant transformation.
We also performed metabolic analyses on the liver, to
see whether β-OHB administration affected a normal
tissue (the mouse mammary organ cannot be freeze-
clamped, so we used the liver as our control). In the β-
OHB-treated animals we observed significant increases
in liver lactate and glycine. A possible explanation for
the absence of a rise in liver glucose despite the increase
in lactate is that glucose in the liver is thought to be
extracellular, because it is immediately phosphorylated
when taken up into liver cells and is exported from them
as soon as it is dephosphorylated. Since the mice had
been normally fed prior to anaesthesia, it is likely that
they were still in a post-absorptive state, so the extracel-
lular glucose concentration would have depended on its
rate of uptake from the hepatic portal vein and its rate
of output into the liver cells. The liver also takes up
lactate for conversion to glucose via gluconeogenesis,
and the measured concentration includes both the intra-
cellular and extracellular pools. Thus, since their meta-
bolic pathways are not directly connected, it is not
necessarily surprising that we observed an elevated liver
lactate in the absence of an elevated liver glucose.
Conclusions
To the best of our knowledge, this study is the first to
test the effect of β-OHB on the growth of a genetically
engineered autochthonous tumour model. We found
that β-OHB administration accelerated the rate of
tumour growth rather than inhibiting it, and that the
tumours did not show evidence of enhanced histone H3
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acetylation. The metabolic profile of these tumours post-
treatment fits with the general phenotype of proliferating
tissues, with increase in ATP, glutamine, serine and
choline-related metabolites.
We have thus found evidence that spontaneous mouse
mammary tumours show a β-hydroxybutyrate paradox
in which tumour growth is promoted by β-OHB, prob-
ably (a) because oxidative metabolism of β-OHB reduces
its concentration below the level at which it could
induce inhibition of tumour growth via inhibition of
histone deacetylation, (b) because the oxidised β-OHB
contributes significantly to the tumour cell’s ATP bal-
ance and perhaps also (c) because the glucose spared
from oxidation is available for increased anabolic synthe-
sis. This β-hydroxybutyrate paradox could explain the
contradictory results in the literature concerning the
anti-cancer effects of β-OHB: perhaps the studies that
showed an anti-cancer effect of β-OHB [3, 5, 7] used
tumour models that preferentially utilised glucose rather
than oxidising β-OHB, and thus accumulated high β-
OHB concentrations that inhibited HDAC, whereas
those that failed to show an anti-cancer effect [8–10]
were conducted on tumour models that preferentially
oxidised β-OHB, thus enhancing their growth rate and
reducing their β-OHB concentration below the level at
which it would slow tumour growth by inhibiting histone
deacylation.
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